SURGERY PARTNERS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.55 USD | -1.17% |
|
+3.02% | -23.26% |
| Mar. 26 | Surgery Partners Unit to Offer $600 Million of Senior Notes | MT |
| Mar. 06 | Surgery Partners Insider Sold Shares Worth $277,633, According to a Recent SEC Filing | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The firm trades with high earnings multiples: 27.13 times its 2024 earnings per share.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -23.26% | 3.1B | C- | ||
| -20.16% | 16.21B | B+ | ||
| +4.50% | 12.44B | B | ||
| +3.98% | 11.58B | B+ | ||
| +9.72% | 10.79B | B+ | ||
| -2.19% | 7.68B | A- | ||
| +18.43% | 7.2B | D | ||
| +4.49% | 6.67B | B- | ||
| +50.89% | 4.66B | - | ||
| -5.12% | 4.25B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SGRY Stock
- Ratings Surgery Partners, Inc.
